

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 47/14, 9/02, 37/02	A1	(11) International Publication Number: WO 94/08622 (43) International Publication Date: 28 April 1994 (28.04.94)
(21) International Application Number: PCT/EP93/02874 (22) International Filing Date: 15 October 1993 (15.10.93) (30) Priority data: MI92A002400 20 October 1992 (20.10.92) IT (71) Applicant (for all designated States except US): SMITH-KLINE BEECHAM FARMACEUTICI S.P.A. [IT/IT]; Via Zambelletti, I-20021 Baranzate di Bollate (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): CHIODINI, Laura [IT/IT]; FONIO, Teodoro [IT/IT]; RANCATI, Gianfranco [IT/IT]; SmithKline Beecham Farmaceutici S.p.A., Via Zambelletti, I-20021 Baranzate di Bollate (IT).		(74) Agent: FLORENCE, Julia, A.; SmithKline Beecham Intellectual Property, Mundells, Welwyn Garden City, Hertfordshire AL7 1EY (GB). (81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN (57) Abstract Pharmaceutical compositions comprising a calcitonin and a polyglycolysed glyceride.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN

5 The present invention relates to novel pharmaceutical compositions containing calcitonins, and to a novel method of enhancing the absorption of a calcitonin across a mucosal membrane.

The calcitonins are a class of pharmacologically active peptides, of both natural and synthetic origin, which contain approximately thirty two amino acids, and which have the ability to regulate serum calcium levels.

10 Various calcitonins, including e.g. natural human, salmon and eel calcitonins and the synthetic eel calcitonin analogue elcatonin are now commercially available and commonly employed, e.g. in the treatment of Paget's disease, Sudeck's disease and osteoporosis.

A considerable and well known problem with the administration of peptides is that they are susceptible to rapid acid and enzyme-induced degradation when administered orally. For this reason, parenteral administration has been, hitherto, the most widely used means of administration and, in the case of peptides of higher molecular weight, such as the calcitonins, has been the only significant effective means of administration.

It is widely recognised that administration by injection can be both inconvenient and unpleasant for the patient, particularly when the administration has to be repeated at regular intervals for long periods, e.g. in the treatment of post-menopausal osteoporosis with calcitonins. Thus, there has been growing interest in the administration of peptides by more acceptable non-invasive alternative routes, for example in the form of sublingual tablets, suppositories, intrapulmonary powders, intranasal drops, sprays, powders, gels, ointments and inserts.

A significant problem with many peptides, particularly those of higher molecular weights, is that they are only poorly absorbed across biological membranes, e.g. mucosal membranes, and thus the bioavailability of the peptide is often very low. Considerable research has therefore been carried out in order to find methods of improving the trans-epithelial absorption of peptides. One approach is to use an adjuvant or absorption enhancer and there are numerous published reports of compounds which are claimed to have peptide absorption-enhancing properties.

Thus, for example, choline esters (EP 214898), acyl carnitines (EP 215697), aldoses and glucosamines (Japanese Pat. Appl. No. 61 126034), ascorbates and salicylates (EP 37943), alpha-cyclodextrin (EP 0094157), pyroglutamate esters (EP 173990), chelating agents (US 4,476,116) ethanol, benzyl alcohol and polyethylene glycol 400 (EP 371010) have been proposed as absorption enhancers.

There are many published reports that surfactants can enhance the absorption of polypeptides, see for example EP 115627 (Armour), GB 2,127,689 (Sandoz), US 4,548,922 (Carey *et al*) and Hirai *et al.*, *Int. J. Pharm.*, 9, 165-184, 1981. However, a recognised problem with surfactant absorption promoters is that, they can cause irritation and histolesion at the site of administration. In some cases this may depend upon the amount employed. These problems become of great importance when the peptide is administered regularly over a prolonged period.

We have now found that absorption of elcatonin following rectal administration is surprisingly enhanced when it is administered as a formulation with a polyglycolysed glyceride, and that such formulations do not cause irritation or histolesion. We have also found a surprising enhancement in absorption when elcatonin is administered as a formulation with a polyglycolysed glyceride, to the colonic mucosa.

In a first aspect therefore the present invention provides a composition containing a calcitonin, a polyglycolysed glyceride and a pharmaceutically acceptable carrier.

The invention also provides a method of enhancing the absorption of a calcitonin across a mucosal membrane, which method comprises co-administering with the calcitonin an effective amount of an absorption enhancer which is a polyglycolysed glyceride.

The polyglycolysed glycerides according to the invention may be saturated or unsaturated. Saturated polyglycolysed glycerides are obtainable by partial alcoholysis of hydrogenated vegetable oil with polyethylene glycol or by esterification of saturated fatty acids with polyethylene glycol and glycerol. Unsaturated polyglycolysed glycerides may be obtained by partial alcoholysis of non-hydrogenated vegetable oil with polyethylene glycol.

Polyglycolysed glycerides which may be employed in the invention include saturated polyglycolysed glycerides consisting of C₈-C₁₈ glycerides and polyethylene glycol esters, such as those available under the trade names Gelucire, e.g. Gelucire 33/01, 35/10, 37/02 or 44/14 ; and Labrafil e.g. Labrafil WL 2514 CS; unsaturated polyglycolysed glycerides consisting of C₁₆-C₂₀ glycerides and polyethylene glycol esters such as those available under the trade name Labrafil e.g. Labrafil WL 2609 BS, or M 2125 CS; and saturated polyglycolysed C₈-C₁₀ glycerides, such as those available under the trade name Labrasol. If desired a mixture of polyglycolysed glycerides may be employed. Particularly preferred polyglycolysed glycerides for use in the present invention include Gelucire 44/14 and Labrasol.


The polyglycolysed glyceride comprises 5 to 100% e.g. 5 to 50% by weight of the total excipients. Thus it may be used as the sole carrier for the calcitonin, or may be admixed with other excipients. It will be appreciated that in view of its potency the weight of calcitonin in the formulation is very low relative to the weight of excipients.

The term calcitonin as used herein is intended to refer to that class of pharmacologically active polypeptides including not only naturally occurring calcitonins but also various derivatives and analogues thereof, e.g. in which one or more of the amino acid residues or sequences naturally present is omitted, replaced, reversed or otherwise derivatised or in which the N or C terminal is modified.

The general term calcitonin, as used hereinafter, is intended to mean all such calcitonins whether naturally occurring or synthetic.

Examples of naturally occurring calcitonins include: human calcitonin, Chemical Abstract Service Registry Number (CAS RN) = 21215-62-3, which has the structure:


10



15

rat calcitonin (CAS RN = 11118-25-5) which has the structure:


20



25


salmon calcitonin (CAS RN = 47931-85-1) which has the structure:

30




eel calcitonin (CAS RN = 57014-02-5) which has the structure:

35




-Thr-Pro-NH₂;


reduced chicken calcitonin I (CAS RN = 96157-98-1) which has the structure:




chicken calcitonin II (CAS RN = 103468-65-1) which has the structure:



ox calcitonin (CAS RN = 26112-29-8) which has the structure:



pig calcitonin (CAS RN = 12321-44-7) which has the structure:



sheep calcitonin (CAS RN = 40988-57-6) which has the structure:

H-Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Ser-
 -Ala-Tyr-Trp-Lys-Asp-Leu-Asn-Asn-Tyr-His-
 5 -Arg-Tyr-Ser-Gly-Met-Gly-Phe-Gly-Pro-Glu-
 -Thr-Pro-NH₂.

Examples of calcitonins wherein one or more amino acids have been omitted are
 the des-[Ser², Tyr²²]-Gly⁸-calcitonins described in US 4,597,900 and the des-[Tyr²²]-
 10 salmon calcitonin described in US 4,304,692.

Examples of calcitonins wherein the naturally occurring sequence has been
 modified include the 1,7-dicarb-calcitonins such as eel 1,7-dicarb-calcitonin (elcatonin
 CAS RN = 60731-46-6) which has the structure:

15 $\overline{\text{---}(\text{CH}_2)_5\text{---}}$
 CO-Ser-Asn-Leu-Ser-Thr-NH-CH-CO-Val-Leu-Gly-
 -Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-
 -Thr-Tyr-Pro-Arg-Thr-Asp-Val-Gly-Ala-Gly-
 -Thr-Pro-NH₂;

20 salmon 1,7-dicarb-calcitonin (CAS RN = 60864-37-1) which has the structure:

25 $\overline{\text{---}(\text{CH}_2)_5\text{---}}$
 CO-Ser-Asn-Leu-Ser-Thr-NH-CH-CO-Val-Leu-Gly-
 -Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-
 -Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-
 -Thr-Pro-NH₂; and

human 1,7-dicarb-calcitonin (CAS RN = 66811-56-1) which has the structure:

30 $\overline{\text{---}(\text{CH}_2)_5\text{---}}$
 CO-Gly-Asn-Leu-Ser-Thr-NH-CH-CO-Met-Leu-Gly-
 -Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-
 -Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-
 35 -Ala-Pro-NH₂.

In the context of the present invention, a particularly preferred calcitonin is
 elcatonin (CAS RN = 60731-46-6). The preparation and properties of elcatonin and
 related 1,7-dicarb-calcitonins are described in British Patent Number 1,516,947 (Toyo
 Jozo).

Another preferred calcitonin is naturally occurring eel calcitonin (CAS RN = 57014-02-5). The preparation and properties of eel calcitonin are described in US 3,988,309 (Matsuda et al).

5 The compositions of the present invention suitably can be administered by methods known in the art for transmucosal and transdermal delivery of pharmacologically active substances. The compositions can be administered to, for example, the rectal, vaginal, nasal, sublingual, buccal, and colonic mucosa and to the skin. They can take the form of drops, aerosols, tablets, capsules, enterically coated solid oral compositions, wafers, gels, ointments, inserts, suppositories, pessaries, patches and membranes.

10 Particular compositions are those intended for administration to the rectal and vaginal mucosa. When the composition is intended for application to the rectal or vaginal mucosa particular dosage forms include pessaries, suppositories, solutions, foams, suspensions, gels, ointments, tablets and soft gelatin capsules.

Compositions for rectal or vaginal administration are generally presented as a
15 solid suppository or a semisolid or liquid formulation filled into a soft gelatin capsule. It will be appreciated therefore that the excipients for use in such suppository or capsule formulations will be selected and if necessary admixed to give a formulation of the desired consistency at room and body temperatures. Thus, the suppository base may for example comprise one or more components selected from an oil, a fat and a polyethylene glycol
20 which can be admixed with the polyglycolysed glyceride. The oil and/or fat preferably comprises one or more triglycerides as the main component, such as coconut oil, fractionated coconut oil (e.g. Miglyol) palm kernel oil, palm fat, cocoa butter or lard. Examples of hard fat suppository bases include Witepsol, and Suppocire. For use in a capsule formulation the polyethylene glycol component is preferably liquid at room
25 temperature such as polyethylene glycol-200, 300, 400 or 600, whereas for a solid suppository a polyethylene glycol of higher molecular weight is preferred. The relative proportions of the excipients will of course depend inter alia on the consistency of the formulation required. If desired the polyglycolysed glyceride may be employed as the sole carrier in a capsule formulation.

30 Compositions adapted for rectal administration as described above are particularly preferred.

Also preferred are compositions which deliver the active ingredient to the colonic mucosa. These include enterically coated compositions intended for oral administration, which may for example take the form of a capsule coated with a coating agent which
35 ensures passage of the calcitonin through the stomach its subsequent release preferably in the colon. Suitable coating agents include anionic polymers such as acrylic acid/methacrylic acid ester copolymers (e.g. Eudragit S). Alternatively the formulation may be incorporated in a controlled release delivery form such as that described in

WO 90/09168. Excipients which may be incorporated in such enteric capsules or controlled release forms include for example those described above for rectal and vaginal formulations.

When the composition is intended for delivery to the nasal mucosa, particular dosage forms are solutions, aerosols, drops, and gels.

Particular dosage forms for buccal and sublingual administration are gels, suspensions, tablets, patches, ointments, solutions, aerosols and wafers.

Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in a sealed container. The sealed container can take the form of a cartridge or refill for use with an atomising device, or it can take the form of a unitary dispensing device such as a single dose nasal inhaler (see French Patent Application FR 2578426) or an aerosol dispenser fitted with a metering valve and which is intended for disposal once the contents of the container have been exhausted. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air or an organic propellant such as a fluorochlorohydrocarbon. Such aerosol dispensers are well known in the art. The aerosol dosage forms can also take the form of a pump-atomiser and such forms are also well known in the art. The atomising or dispensing devices for dispensing aerosol sprays typically are designed to dispense particles of a size greater than 10 micrometres. In order to ensure that significant quantities of the composition remain in contact with the oral or nasal mucosa, and are not inhaled, the particles suitably are approximately 10-160 micrometres in size.

When the composition is intended to be administered as a liquid spray, the viscosity of the liquid composition can be adjusted as necessary according to known methods to ensure that the composition is sprayable.

Compositions in the form of wafers may be for example as described in PCT/GB91/00651. Such wafers are formed substantially of starch and suitably have a thickness of from 0.3 to 1.0 mm.

The compositions according to the present invention may also contain an aqueous or physiologically acceptable non-aqueous solvent or liquid carrier. Examples of non-aqueous solvents or carriers are alcohols, particularly polyhydroxy alcohols such as propylene glycol and glycerol, and vegetable and mineral oils. Such non-aqueous solvents or carriers can if desired be admixed with water to form for example emulsions.

The formulations of the present invention may also contain excipients such as antioxidants, stabilisers, preservatives (e.g. parabens or benzyl alcohol), surfactants e.g. sodium lauryl sulphate, agents for adjusting viscosity, agents for adjusting tonicity (e.g. sodium chloride, glycine or mannitol), and buffering agents.

The compositions may also contain glycyrrhizinic acid or a salt thereof, e.g. sodium or potassium glycyrrhizinate or ammonium glycyrrhizinate. The concentration of the glycyrrhizinate is typically at least 0.1% (w/w), suitably 0.1 to 10% (w/w), and preferably 0.2 to 5% (w/w) of the total weight of the composition. In suppositories, and soft gelatin capsules for rectal or vaginal administration the glycyrrhizinate is suitably present in an amount corresponding to between 0.1 g and 2 g per 100 g of composition. Preferably the glycyrrhizinate is present in an amount corresponding to between 0.2 g and 1 g per 100 g.

The compositions can also contain a protease inhibitor, preferably a non-surfactant protease inhibitor, for example as described in EP 127535.

The pH of the compositions of the present invention can vary within a broad range according to the chemico-physical properties of the different ingredients in the compositions. However, suitably the pH of the composition is in the range from pH 3 to 8, preferably from approximately pH 3.5 to approximately pH 7. In order to regulate the pH and maintain a suitable value, a buffering agent may be included in the composition. Examples of buffering agents which may be used include citrates, (for example a mixture of citric acid and sodium citrate), acetates, phosphates and adipates. In addition to a buffering agent such as those described hereinabove, an alkali metal hydroxide e.g. sodium hydroxide may be incorporated to regulate the pH.

For the avoidance of doubt, compositions containing a combination of a calcitonin, a Gelucire, ammonium glycyrrhizinate and benzyl alcohol are specifically excluded from this application, such formulations being described in International application no. WO 93/06854.

In general, the above-mentioned compositions can be made according to well known pharmaceutical procedures, see for example Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Company, 1985. Soft gelatin capsules may be prepared for example as described in WO 84/03417 or EPA 122463.

The compositions of the present invention can be used in the treatment of diseases such as Paget's disease (osteitis deformans), osteoporosis including post-menopausal osteoporosis, Sudeck's disease and various hypercalcaemic conditions (see, for example, the Physician's Desk Reference, 42nd Edition, 1988, pages 1796 and 1797).

The quantity of pharmacologically active substance in a unit dose of the compositions of the present invention will vary according to the potency of the calcitonin and the nature of the composition. However, in general, a unit dose of a composition intended for human use typically contains between 1 and 1000 International Units (I.U.) of a calcitonin. For elcatonin, a unit dose in general contains from 5 to 200 I.U. A unit dose adapted for colonic administration preferably contains from 40-800 I.U. of elcatonin. The compositions will be administered to the patient in dosages which contain an amount of

calcitonin effective to treat the disease in question. A typical dosage regimen for elcatonin is from 5 to 200 I.U. per day (or 40-800 I.U. for colonic administration) which may be administered in a single dose or in divided doses for example on consecutive or alternate days.

- 5 The term "International Unit" refers to the appropriate International Reference Preparation (I.R.P.) of human, salmon or porcine calcitonins, or elcatonin, established by the National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, United Kingdom.

The invention will now be illustrated in greater detail by the following examples.

10

Formulations for vaginal, rectal or oral administration

Example 1

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Polyethylene glycol 600 (g)	550.0	550.0
Gelucire 44/14 (g)	400.0	400.0
Distilled water (g)	44.1	49.1
Ammonium glycyrrhizinate (g)	5.0	-
Sodium chloride (mg)	300.0	300.0
Sodium citrate dihydrate (mg)	231.5	231.5
Sodium hydroxide (mg)	350	-
Citric acid (mg)	18.5	18.5

Method

- 15 Mix together the citric acid, sodium citrate dihydrate, sodium chloride, distilled water, elcatonin and if appropriate ammonium glycyrrhizinate and sodium hydroxide in a water bath regulated at a temperature of about 70°C, and then cool to about 55°C. Melt the Gelucire at about 50 to 60°C, add the polyethylene glycol 600, cool to about 45 to 50°C and then add the above solution, under stirring.

- 20 The final mixture, cooled to about 30°C, may be filled into soft gelatin capsules for rectal or vaginal administration (1 g formulation (a) each capsule) or into soft gelatin capsules (300 mg formulation (b) per capsule) for oral administration. Optionally, the mixture may be dried under vacuum and filled into hard gelatin capsules (290 mg formulation (b) per capsule) for oral administration. Capsules for oral administration may
- 25 be coated with the following coating :

	mg/capsule
Eudragit S	33.0
Talc	9.0
Dibutylphthalate	6.6
PEG 6000	0.9

Example 2

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Polyethylene glycol 600 (g)	580.0	580.0
Gelucire 44/14 (g)	420.0	420.0

Method

- 5 Melt the Gelucire at about 50 to 60°C, add the polyethylene glycol, cool to about 45 to 50°C and add the elcatonin. The mixture may be filled into soft gelatin capsules for rectal, vaginal or oral administration and optionally coated for oral administration as in Example 1. Alternatively for oral administration the mixture may be filled into hard gelatin capsules coated as above.

10

Example 3

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Gelucire 35/10 (g)	950.0	950.0
Distilled water (g)	44.1	49.1
Ammonium glycyrrhizinate (g)	5.0	-
Sodium chloride (mg)	300.0	300.0
Sodium citrate dihydrate (mg)	231.5	231.5
Sodium hydroxide (mg)	350.0	-
Citric acid (mg)	18.5	18.5

Method

- 15 The formulations are prepared in a similar manner to Example 1, without the inclusion of polyethylene glycol.

Example 4

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Gelucire 35/10 (g)	1000.0	1000.0

Method

- 5 Melt the Gelucire at about 50 to 60°C, cool to about 45 to 50°C and add the elcatonin. The mixture may be filled into gelatin capsules and optionally coated as in Examples 1 and 2.

Example 5

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Gelucire 37/02 (g)	950.0	950.0
Distilled water (g)	49.1	44.1
Ammonium glycyrrhizinate (g)	-	5.0
Sodium chloride (mg)	300.0	300.0
Sodium citrate dihydrate (mg)	231.5	231.5
Sodium hydroxide (mg)	-	350.0
Citric acid (mg)	18.5	18.5

10

Method

The formulations are prepared in a similar manner to Example 1, without the inclusion of polyethylene glycol.

15 **Example 6**

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Gelucire 37/02 (g)	1000.0	1000.0

Method

Melt the Gelucire at about 50 to 60°C, cool to about 45 to 50°C and add the elcatonin. The mixture may be filled into gelatin capsules and optionally coated as in Examples 1 and 2.

5

Example 7

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Gelucire 44/14 (g)	450.0	450.0
Labrafil M2125CS (g)	500.0	500.0
Distilled water (g)	44.1	49.1
Ammonium glycyrrhizinate (g)	5.0	-
Sodium chloride (mg)	300.0	300.0
Sodium citrate dihydrate (mg)	231.5	231.5
Sodium hydroxide (mg)	350.0	-
Citric acid (mg)	18.5	18.5

Method

Melt the Gelucire at about 50 to 60°C, add the Labrafil, cool to around 45 to 50°C and add the buffered elcatonin solution, as in Example 1. The mixture may be filled into capsules as described in Example 1.

10

Example 8

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Gelucire 44/14 (g)	500.0	500.0
Labrafil M2125CS (g)	500.0	500.0

15 **Method**

Melt the Gelucire at about 50 to 60°C, add the Labrafil, cool to about 45 to 50°C and add the elcatonin with stirring. The mixture may be filled into capsules as described in Examples 1 and 2.

Example 9

	a	b
Elcatonin (mg)	7.4, 14.8 or	25, 50 or 100
(6500 I.U./mg potency)	29.6	
Labrasol (g)	950.0	950.0
Distilled water (g)	49.1	49.1
Sodium chloride (mg)	300.0	300.0
Sodium citrate dihydrate (mg)	231.5	231.5
Citric acid (mg)	18.5	18.5

Method

Prepare the buffered elcatonin solution as in Example 1 and then add the Labrasol
 5 under stirring. The mixture may be filled into capsules as described in Example 1.

Example 10

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Labrasol (g)	1000.0	1000.0

Method

10 Mix the Labrasol and elcatonin under stirring. The mixture may be filled into
 capsules as described in Examples 1 and 2.

Example 11

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Polyethylene glycol 600 (g)	550.0	550.0
Labrasol (g)	400.0	400.0
Distilled water (g)	49.1	44.1
Ammonium glycyrrhizinate (g)	-	5.0
Sodium chloride (mg)	300.0	300.0
Sodium citrate dihydrate (mg)	231.5	231.5
Sodium hydroxide (mg)	-	350.0
Citric acid (mg)	18.5	18.5

Method

Mix the Labrasol with the polyethylene glycol and add the buffered elcatonin solution with stirring. The mixture may be filled into capsules as in Example 1.

5

Example 12

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Polyethylene glycol 600 (g)	580.0	580.0
Labrasol (g)	420.0	420.0

Method

Analogous to Example 2.

10

Example 13

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Labrafil M2125CS (g)	1000.0	1000.0

Method

Analogous to Example 10.

15

Example 14

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 I.U./mg potency)	or 29.6	
Labrafil WL 2609 BS (g)	1000.0	1000.0

Method

Analogous to Example 10.

20

Example 15

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 IU./mg potency)	or 29.6	
Labrasol (g)	667.0	667.0
Gelucire 44/14 (g)	333.0	333.0

Method

Analogous to Example 8.

5

Example 16

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 IU./mg potency)	or 29.6	
Labrafil WL 2609 BS (g)	500.0	500.0
Gelucire 35/10 (g)	500.0	500.0

Method

Analogous to Example 8.

10

Example 17

	a	b
Elcatonin (mg)	7.4, 14.8	25, 50 or 100
(6500 IU./mg potency)	or 29.6	
Labrasol (g)	500.0	500.0
Gelucire 44/14 (g)	500.0	500.0

Method

Analogous to Example 8.

15

Suppository for rectal or vaginal administration**Example 18**

Elcatonin (mg)	15.4
(6500 IU./mg potency)	
Hard fat (g)	750.0
Labrafil WL 2514 CS (g)	750.0

Method

- 5 The hard fat and the Labrafil are melted and mixed at 50 to 60°C, cooled to 45 to 50°C and the elcatonin is added with stirring. The mass obtained is poured into suppository moulds and cooled to room temperature, to give suppositories of 1.5 g each.

Solution for nasal, sublingual, buccal, rectal or vaginal administration10 **Example 19**

	a	b	c
Elcatonin (mcg)	3690	7380	3690
(6500 IU./mg potency)			
Gelucire 44/14 (g)	8.0	8.0	8.0
Polyethylene glycol 600 (g)	11.0	11.0	11.0
Citric acid (mg)	37.0	37.0	37.0
Sodium citrate dihydrate (mg)	463.0	463.0	463.0
Sodium chloride (mg)	600.0	600.0	600.0
Benzyl alcohol (g)	2.0	-	-
Methyl p-hydroxybenzoate (mg)	-	130.0	-
Propyl p-hydroxybenzoate (mg)	-	20.0	-
Benzalkonium chloride (mg)	-	-	10.0
Distilled water		q.s. to 100 ml	
1N sodium hydroxide		q.s. to pH6	

Method

- 15 All the components except elcatonin are dissolved at about 35 to 40°C, in 80% of the water and the resulting solution cooled to room temperature. The elcatonin is dissolved in the remaining 20% of the water and the two solutions are mixed under stirring. For nasal, sublingual or buccal use the solution may be administered at a volume of 100 µl and for rectal or vaginal administration at 200 to 400 µl.

Dosage form for transdermal administration**Example 20**

Elcatonin (mg)		
(6500 IU./mg potency)	6.0	6.0
Gelucire 44/14 or 35/10 (g)	8.0	8.0
Polyethylene glycol 600 (g)	11.0	11.0
Ammonium glycyrrhizinate (g)	2.0	-
Carbopol 934 (g)	2.0	2.0
Citric acid (mg)	37.0	37.0
Sodium citrate dihydrate (mg)	463.0	463.0
Sodium chloride (mg)	600.0	600.0
Distilled water	q.s. to 100 g	
1N NaOH	q.s. to pH 6	

Method

5. The formulation of Example 20 is prepared by mixing together the Gelucire, polyethylene glycol 600, citric acid, sodium citrate dihydrate, sodium chloride, Carbopol 934, sodium hydroxide, ammonium glycyrrhizinate (when used) and part of distilled water in a water bath regulated at a temperature of about 70°C. To the resulting gel, cooled to room temperature, a solution of elcatonin in the remaining part of distilled water, is then
- 10 added. The final gel is filled into patches of 500 mg each.

Formulation for rectal or vaginal administration**Example 21**

Elcatonin (mg)	
(6500 IU./mg potency)	14.8
Polyethylene glycol 600 (g)	550.0
Gelucire 44/14 (g)	400.0
Distilled water (g)	49.449
Sodium chloride (mg)	300.0
Sodium citrate dihydrate (mg)	231.5
Citric acid (mg)	18.5
Sodium hydroxide (mg)	1.0

Method

The citric acid, sodium citrate dihydrate, sodium chloride, sodium hydroxide, distilled water and elcatonin, were mixed together in a water bath at a temperature of about 55°C. The Gelucire was melted at about 50 to 60°C, and the polyethylene glycol 600 added. This mixture was cooled to about 45 to 50°C and then added to the above solution, under stirring.

The final mixture, cooled to about 30°C, may be filled into soft gelatin capsules (1 g each capsule) for rectal or vaginal administration.

10 **Formulations for vaginal, rectal or oral administration****Example 22**

	a	b
Elcatonin (mg)	7.4, 14.8	50, 100, 200
(6500 I.U./mg potency)	or 29.6	or 400
Labrasol (g)	500.0	500.0
Polyethylene glycol 600 (g)	398.5	398.5
Polyethylene glycol 200 (g)	100.0	100.0
Sodium lauryl sulphate (g)	1.5	1.5

Method

Dissolve elcatonin in polyethylene glycol 200, then add and mix together all the other components.

The final mixture may be filled into capsules as described in Example 1.

Example 23

Elcatonin (mg)	
(6500 I.U./mg potency)	2.55
Labrasol (g)	500.0
Polyethylene glycol 600 (g)	398.5
Polyethylene glycol 200 (g)	100.0
Sodium lauryl sulphate (g)	1.5

20 **Method**

The formulation of Example 23 was prepared as described in Example 22.

Example 24

	a	b
Elcatonin (mg)	7.4, 14.8	50, 100, 200
(6500 I.U./mg potency)	or 29.6	or 400
Labrasol (g)	500.0	500.0
Polyethylene glycol 600 (g)	348.5	348.5
Polyethylene glycol 200 (g)	100.0	100.0
Sodium lauryl sulphate (g)	1.5	1.5
Distilled water (g)	44.45	44.45
Ammonium glycyrrhizinate (g)	5.0	5.0
Sodium chloride (mg)	300.0	300.0
Sodium citrate dihydrate (mg)	231.5	231.5
Citric acid (mg)	18.5	18.5

Method

- Mix together the citric acid, sodium citrate dihydrate, sodium chloride, ammonium glycyrrhizinate, distilled water and elcatonin, in a water bath at a temperature of about 55°C. Mix together polyethylene glycol 200, polyethylene glycol 600 and Labrasol. Blend the two mixtures and cool to room temperature.

The final mixture may be filled into capsules as described in Example 1.

10 Example 25

	a	b
Elcatonin (mg)	7.4, 14.8	50, 100, 200
(6500 I.U./mg potency)	or 29.6	or 400
Labrasol (g)	857.0	857.0
Polyethylene glycol 200 (g)	33.0	33.0
Sodium lauryl sulphate (g)	10.0	10.0
Distilled water (g)	50.0	50.0
Adipic acid (g)	40.0	40.0
Sodium acetate trihydrate (g)	10.0	10.0

Method

- Dissolve the elcatonin in polyethylene glycol 200 and distilled water, then add Labrasol, sodium lauryl sulphate, adipic acid and sodium acetate trihydrate and mix together.

The final mixture may be filled into capsules as described in Example 1.

Trial A

The absorption enhancing property of a polyglycolysed glyceride (Gelucire 44/14) was demonstrated by the following trial.

- 5 The preparation reported in Example 21, containing 40% of Gelucire 44/14, was compared, in a test of pharmacodynamic activity in rabbits i.e. lowering of calcium concentration in the serum, with a reference preparation without Gelucire, having the following composition :

10 **Reference preparation**

Elcatonin (mg)	
(6500 I.U./mg potency)	14.8
Polyethylene glycol 600 (g)	880.0
Polyethylene glycol 4000 (g)	70.0
Distilled water (g)	49.449
Sodium chloride (mg)	300.0
Sodium citrate dihydrate (mg)	231.5
Citric acid (mg)	18.5
Sodium hydroxide (mg)	1.0

(Polyethylene glycol 4000 was added in order to have a viscosity similar to that of the preparation of Example 21; the preparation method is similar to that of Example 21).

- 15 The preparations were administered rectally with a small catheter, in the amount of 0.5 g/Kg body weight (corresponding to about 50 I.U./Kg) to groups of 6, conscious, fasted overnight, New Zealand rabbits, weighing about 2 Kg.

Serum calcium concentration was measured (with an atomic absorption spectrophotometer VARIAN 30/40) on blood samples obtained in each animal, from the lateral vein of ear, 0, 60, 120, 180 and 240 min after administration of the products.

- 20 The results, expressed as residual percentage of serum calcium concentration as compared with baseline values (0 time), are reported in Table 1.

Table 1

	Residual percentage of serum calcium as compared with baseline values (mean values \pm standard errors)				
	0 min	60 min	120 min	180 min	240 min
Preparation of Example 21	100.0	77.2 ± 2.5	81.6 ± 2.6	92.8 ± 1.3	94.7 ± 1.3
Reference preparation without Gelucire	100.0	83.7 ± 2.8	93.9 ± 1.1	95.1 ± 2.6	97.5 ± 3.6

Trial B

5 The absorption enhancing property of a polyglycolysed glyceride (Labrasol) is demonstrated by this trial.

The preparation reported in Example 23, containing 50% of Labrasol, was compared, in a test of pharmacodynamic activity in rats i.e. lowering of calcium concentration in the serum, with a reference preparation without Labrasol (Labrasol was completely substituted by polyethylene glycol 600).

10 The preparations were administered intracolonicly with a small catheter, in the volume of 2 ml/Kg body weight (corresponding to about 30 I.U./Kg) to groups of 4, conscious, fasted overnight, Sprague Dawley rats, weighing about 220 \pm 20 g.

Serum calcium concentration was measure (with an atomic absorption spectrophotometer VARIAN 30/40) on blood samples obtained in each animal, from the
15 caudal vein, 0, 60 and 120 min after administration of the products.

The results, expressed as a residual percentage of serum calcium concentration as compared with baseline values (0 time) are reported in Table 2.

Table 2

	Residual percentage of serum calcium as compared with baseline values (mean values \pm standard errors)		
	0 min	60 min	120 min
Preparation of Example 23	100.0	79.5 ± 3.0	88.2 ± 5.8
Reference preparation without Labrasol	100.0	96.0 ± 2.5	99.1 ± 1.4

20

CLAIMS:

1. A pharmaceutical composition comprising a calcitonin and a polyglycolysed glyceride.
5
2. A composition according to claim 1 wherein the polyglycolysed glyceride is a saturated polyglycolysed glyceride.
3. A composition according to claim 2 wherein the saturated
10 polyglycolysed glyceride consists of C₈-C₁₈ glycerides and polyethylene glycol esters.
4. A composition according to claim 2 wherein the saturated polyglycolysed glyceride contains C₈-C₁₀ glycerides.
5. A composition according to claim 1 wherein the polyglycolysed
15 glyceride is unsaturated.
6. A composition according to claim 5 wherein the unsaturated polyglycolysed glyceride consists of C₁₆-C₂₀ glycerides and polyethylene glycol esters.
20
7. A composition according to any one of claims 1 to 6 wherein the calcitonin is elcatonin.
8. A composition according to any one of claims 1 to 7 adapted for rectal,
25 vaginal, nasal, sublingual, buccal, oral, transdermal or colonic administration.
9. A composition according to claim 8 which comprises a controlled release delivery form adapted for oral administration and subsequent release of the active ingredient in the region of the colonic mucosa.
30
10. A composition according to any one of claims 1 to 9 in the form of a unit dose which contains from 1 to 1000 I.U. of a calcitonin.
11. A composition according to any one of claims 1 to 10 which has a pH in
35 the range from approximately 3.5 to approximately 7.

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/EP 93/02874A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K47/14 A61K9/02 A61K37/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR,A,2 312 260 (CIBA GEIGY AG.) 24 December 1976 see claim 1 see page 4, line 35 - page 5, line 20 ----	1,5,6, 10,11
P,X	EP,A,0 535 827 (CIBA-GEIGY AG.) 7 April 1993 see the whole document -----	1-11

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

21 January 1994

Date of mailing of the international search report

04.02.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 93/02874

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-2312260	24-12-76	AU-B- 507537	21-02-80
		AU-A- 1425276	01-12-77
		BE-A- 842189	25-11-76
		CA-A- 1098444	31-03-81
		DE-A- 2623074	09-12-76
		GB-A- 1548984	18-07-79
		JP-A- 51144721	13-12-76
		NL-A- 7605559	30-11-76

EP-A-0535827	07-04-93	AU-A- 2537992	01-04-93
		JP-A- 5213773	24-08-93
